Farther Finance Advisors’s Akebia Therapeutics AKBA Stock Holding History

Farther Finance Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.13K	Buy	8,039 +2,870	+56%	+$3.42K	﹤0.01%	4482
2026 Q1	$7.29K	Buy	5,169 +4,757	+1,155%	+$6.54K	﹤0.01%	4304
2025 Q4	$663	Hold	412	–	–	﹤0.01%	5005
2025 Q3	$1.13K	Hold	412	–	–	﹤0.01%	4336
2025 Q2	$1.5K	Hold	412	–	–	﹤0.01%	3792
2025 Q1	$787	Buy	+412	New	+$841	﹤0.01%	3686

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $393M AUM 30.08% 1-Year Est. Return

LPT

Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return

JWCA

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

EWS

Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return

Farther Finance Advisors's AKBA Position: Q2 2026 in Review

Farther Finance Advisors increased its Akebia Therapeutics (AKBA) stake by 56% in Q2 2026, buying an estimated $3.42K and bringing the position to 8,039 shares worth $9.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4482.

Farther Finance Advisors first reported a position in AKBA in Q1 2025 and has held it in 6 quarters since. 17 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Farther Finance Advisors held 8,039 shares of Akebia Therapeutics worth $9.13K as of Q2 2026.
Farther Finance Advisors bought 2,870 Akebia Therapeutics shares in Q2 2026, an estimated $3.42K.
Akebia Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4482 holding.
Farther Finance Advisors first reported a position in Akebia Therapeutics in Q1 2025 and has held it in 6 quarters since.
17 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.